Single Dose Study of Controlled-Release Paroxetine Tablets in Healthy Japanese Male Subjects

GlaxoSmithKline (GSK)

Status and phase: Completed; Phase 1

Conditions: Depressive Disorder

Treatments: Drug: Paroxetine 12.5 milligrams tablet; Drug: Paroxetine 25 milligrams tablet; Drug: Paroxetine 50 milligrams tablet

Study type: Interventional

Funder types: Industry

Identifiers

NCT00938184

112811

Details and patient eligibility

About

The primary purpose of this study is to to assess the pharmacokinetics of paroxetine after single doses of paroxetine CR at the dose levels of 12.5, 25 and 50mg in healthy Japanese male volunteers.

Full description

This clinical trial is to characterize the pharmacokinetic profile after single oral doses of the proposed final market tablet formulations of paroxetine CR in Japan (the 12.5mg and 25mg tablets), at the dose levels of 12.5, 25 and 50mg in the healthy male Japanese volunteers. Treatment sequence of the 3 dose levels in each subject is randomized.

Enrollment: 18 patients

Sex: Male

Ages: 20 to 64 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy Japanese adult males between 20 and 64 years of age inclusive
• BMI 18.50 or higher and < 25.00 kg/m2, and bodyweight 50 kg or higher
• Non-smokers
• AST, ALT, ALP, gamma-GTP and total-bilirubin are below the upper limit of normal range
• QTc(B) interval <450 msec
• Able to attend all visits and complete the study
• Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form

Exclusion criteria

• Any clinically relevant abnormality on the screening physical examination, vital signs, 12-lead ECG and/or clinical laboratory tests
• Medical history that is not considered as eligible for inclusion in this study by the investigator
• Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of asymptomatic gallstones)
• History of psychiatric disorder or suicide attempts or behaviours
• History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs
• History of sensitivity to any of the paroxetine formulations, or components thereof
• Positive for urine drug screening
• Participation in another clinical study or post-marketing study in which the subject is or will be exposed to an investigational or a non-investigational product or device
• Participation in a clinical study or post-marketing study with an investigational or a non-investigational product or device within 4 months of preceding the first dose of study medication
• History of drug or other allergy, or idiosyncrasy, excluding a pollen allergy without current symptoms
• History of drug abuse, or current conditions of drug abuse or alcoholism
• History of regular alcohol consumption exceeding, on average, 14 drinks/week (1 drink = 150 mL of wine or 350 mL of beer or 45 mL of 80 proof distilled spirits) within 6 months of screening
• Use of prescription or no-prescription drugs, including vitamins, crude drug, herbal and dietary supplements (including St John's Wort) within 14 days prior to the first dose of study medication
• Unwillingness or inability to follow the procedures outlined in the protocol
• Consumption of grapefruit or grapefruit-containing products from 7 days prior to the first dose of study medication
• Positive for syphilis, HIV antibody and antigen, Hepatitis B surface antigen, Hepatitis C antibody or HTLV-1 antibody
• Donation of blood in excess of 400mL within the previous 4 months or 200mL within the previous 1 month to the first dose of study medication

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

18 participants in 6 patient groups

Treatment sequence A/B/C

Experimental group

Description:

Eligible subjects will be randomized in sequence A/B/C and will receive A: single tablet of paroxetine 12.5 milligrams, B: single tablet of paroxetine 25 milligrams and C: two tablets of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.

Treatment:

Drug: Paroxetine 50 milligrams tablet

Drug: Paroxetine 25 milligrams tablet

Drug: Paroxetine 12.5 milligrams tablet

Treatment sequence A/C/B

Experimental group

Description:

Eligible subjects will be randomized in sequence A/C/B and will receive A: single tablet of paroxetine 12.5 milligrams, C: two tablets of paroxetine 25 milligrams and B: single tablet of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.

Treatment:

Drug: Paroxetine 50 milligrams tablet

Drug: Paroxetine 25 milligrams tablet

Drug: Paroxetine 12.5 milligrams tablet

Treatment sequence B/A/C

Experimental group

Description:

Eligible subjects will be randomized in sequence B/A/C and will receive B: single tablet of paroxetine 25 milligrams, A: single tablet of paroxetine 12.5 milligrams and C: two tablets of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.

Treatment:

Drug: Paroxetine 50 milligrams tablet

Drug: Paroxetine 25 milligrams tablet

Drug: Paroxetine 12.5 milligrams tablet

Treatment sequence B/C/A

Experimental group

Description:

Eligible subjects will be randomized in sequence B/C/A and will receive B: single tablet of paroxetine 25 milligrams, C: two tablets of paroxetine 25 milligrams and A: single tablet of paroxetine 12.5 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.

Treatment:

Drug: Paroxetine 50 milligrams tablet

Drug: Paroxetine 25 milligrams tablet

Drug: Paroxetine 12.5 milligrams tablet

Treatment sequence C/A/B

Experimental group

Description:

Eligible subjects will be randomized in sequence C/A/B and will receive C: two tablets of paroxetine 25 milligrams, A: single tablet of paroxetine 12.5 milligrams and B: single tablet of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.

Treatment:

Drug: Paroxetine 50 milligrams tablet

Drug: Paroxetine 25 milligrams tablet

Drug: Paroxetine 12.5 milligrams tablet

Treatment sequence C/B/A

Experimental group

Description:

Eligible subjects will be randomized in sequence C/B/A and will receive C: two tablets of paroxetine 25 milligrams, B: single tablet of paroxetine 25 milligrams and A: single tablet of paroxetine 12.5 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.

Treatment:

Drug: Paroxetine 50 milligrams tablet

Drug: Paroxetine 25 milligrams tablet

Drug: Paroxetine 12.5 milligrams tablet